Table 1 Comparison of patients’ demographic and clinical characteristics between the two groups
Effective ibutilide group(n = 115) | Ineffective ibutilide group(n = 77) | P | |
|---|---|---|---|
Age (years old) | 64.46 ± 11.02 | 61.26 ± 11.72 | 0.852 |
Weight(kg) | 68.12 ± 11.72 | 72.83 ± 12.08 | 0.008* |
Duration of atrial fibrillation (months) | 34.67 ± 55.68 | 66.52 ± 95.21 | 0.008* |
Male | 80(69.6%) | 61(79.2%) | 0.138 |
Female | 35(30.4%) | 16(20.8%) | |
Heart failure | 11(9.6%) | 10(13.0%) | 0.457 |
Hypertension | 40(34.8%) | 37(48.0%) | 0.066 |
Diabetes | 24(21.1%) | 12(15.6%) | 0.358 |
Coronary heart disease | 13(11.3%) | 11(14.3%) | 0.540 |
Stroke history | 9(7.8%) | 9(11.7%) | 0.368 |
Peripheral vascular disease | 27(23.5%) | 19(24.7%) | 0.849 |
CHA2DS2-VAScscore | 1.96 ± 1.70 | 2.16 ± 1.71 | 0.377 |
LA diameter(mm) | 44.39 ± 5.80 | 47.36 ± 6.10 | 0.002* |
EF(%) | 60.48 ± 8.30 | 61.19 ± 9.23 | 0.384 |
NT-proBNP baseline level(pg/mL) | 854.85 ± 770.84 | 662.88 ± 659.18 | 0.030* |